Home / Seminar & Event /Past Seminars / (313) Anti-infective and Neurodegenerative Drug Discovery -Something Old, Something New...
Home / Seminar & Event /Past Seminars / (313) Anti-infective and Neurodegenerative Drug Discovery -Something Old, Something New...
(313) Anti-infective and Neurodegenerative Drug Discovery -Something Old, Something New...
Seminar: (313) Anti-infective and Neurodegenerative Drug Discovery -Something Old, Something New...
Speaker: Prof. James Leahy, Department of Chemistry, University of South Florida, Tampa, USA
Time: 2018-06-16 10:00 to 2018-06-16 11:00
Venue: Meeting room (406), Building 24
Organizer:

Prof. Jon Antilla 


Abstract: Infectious disease and neurodegenerative disorders both represent significant areas of need from the perspective of threats to global health. Despite the desperate need for new drugs in each of these therapeutic arenas, they remain relatively under investigated by the pharmaceutical industry, primarily because of the obvious challenges associated with making either of these areas profitable ventures. For this reason, our lab is actively pursuing the discovery of potential small molecule leads aimed at infectious diseases and neurodegenerative disorders with an eye toward the development of viable new drugs with suitable activity as well as ADME and pharmacokinetic profiles. Progress in these endeavors will be reported, including novel scaffolds and natural products, some of which are simultaneously well known and yet understudied.


Jim_Leahy_CV.pdf

TJUT2018_James Leahy_Abstract.pdf


(313) Anti-infective and Neurodegenerative Drug Discovery -Something Old, Something New...
Seminar: (313) Anti-infective and Neurodegenerative Drug Discovery -Something Old, Something New...
Speaker: Prof. James Leahy, Department of Chemistry, University of South Florida, Tampa, USA
Time: 2018-06-16 10:00 to 2018-06-16 11:00
Venue: Meeting room (406), Building 24
Organizer:

Prof. Jon Antilla 


Abstract: Infectious disease and neurodegenerative disorders both represent significant areas of need from the perspective of threats to global health. Despite the desperate need for new drugs in each of these therapeutic arenas, they remain relatively under investigated by the pharmaceutical industry, primarily because of the obvious challenges associated with making either of these areas profitable ventures. For this reason, our lab is actively pursuing the discovery of potential small molecule leads aimed at infectious diseases and neurodegenerative disorders with an eye toward the development of viable new drugs with suitable activity as well as ADME and pharmacokinetic profiles. Progress in these endeavors will be reported, including novel scaffolds and natural products, some of which are simultaneously well known and yet understudied.


Jim_Leahy_CV.pdf

TJUT2018_James Leahy_Abstract.pdf